MAGNETISMM-7 A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Latest Information Update: 13 Apr 2025
At a glance
- Drugs Elranatamab (Primary) ; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms MAGNETISMM-7
- Sponsors Pfizer
- 15 Jun 2023 Trial design presented at the 28th Congress of the European Haematology Association
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2023 According to Adaptive Biotechnologies Media Release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Hybrid Congress.